Alemtuzumab, the anti-CD52 monoclonal antibody used to treat relapsing–remitting MS (RRMS), appears to protect neuroaxonal structure compared to other first-line injectable treatments, a multinational study has found. The findings comes from a five year study that used optical coherence tomography (OCT) measures of neuroaxonal structure to compare the effects of alemtuzumab treatment in 24 RRMS ...
Alemtuzumab preserves neuroaxonal structure in MS
By Michael Woodhead
4 Mar 2020